Disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica spectrum disorder accumulates through attacks that target the central nervous system.
These severe inflammatory events can cause permanent vision loss from optic neuritis, paralysis from myelitis, or fatal brainstem syndromes. Because a single relapse can trigger irreversible harm, prompt access to disease-modifying therapies is essential for preventing long-term disability progression.
Researchers Evaluate Ethics of Placebo in Rare Brain Disorder Trial
- What happened: Researchers evaluated the ethics of using a sugar pill (placebo) instead of an active medicine in a major clinical trial for a rare autoimmune brain disorder.
- Why it matters: Participants who received the placebo experienced a 45.7% relapse rate and required hospitalization, raising questions about trial design standards when approved treatments already exist.
Clinical Trial Design and Ethical Standards Under Scrutiny
The Nature Medicine commentary centers on a phase 3 randomized controlled trial of obinutuzumab beta (MIL62) directed by Lei Wu, Liangliang Gu, Weihao Fan, and colleagues across 32 medical centers in China starting in August 2022.
While the trial demonstrated a markedly decreased risk of relapse in participants treated with obinutuzumab beta compared to those given a placebo, the commentary argues that incorporating a concurrent placebo arm violated the ethical principles of the Declaration of Helsinki. Under international guidelines, testing a new intervention against a placebo is considered unacceptable when proven, effective therapeutic options already exist for the targeted condition.
Historically, foundational placebo-controlled trials published between 2019 and 2020 established the efficacy of B-cell depleting agents and complement inhibitors for neuromyelitis optica spectrum disorder. These investigations justified placebo usage at the time because high-quality comparative evidence was lacking. However, the regulatory landscape shifted significantly before the obinutuzumab beta trial commenced.
In China, the National Medical Products Administration approved satralizumab in April 2021 and inebilizumab in March 2022. Additional therapies such as eculizumab and ravulizumab received subsequent approvals in October 2023 and August 2025, respectively. Rituximab gained regulatory approval in Japan in June 2022 and held widespread acceptance under Chinese national guidelines based on extensive observational data and prior clinical trials.
Placebo Group Suffers High Relapse and Disability Rates
The consequences of assigning participants to a placebo group materialized clearly over the course of the study. A staggering 45.7% of participants in the placebo arm experienced disease relapses, all of which necessitated hospitalization.
Also, 22.9% of individuals in the placebo group demonstrated measurable worsening on the Expanded Disability Status Scale at their final visit. By comparison, the obinutuzumab beta treatment arm reported a relapse rate of only 4.4% and an Expanded Disability Status Scale worsening rate of 8.4%.
These divergent outcomes highlight the real-world dangers faced by trial participants when active treatments are withheld. Alternative trial methodologies, such as non-inferiority designs or the integration of external historical controls, were available to investigators. As proof of feasibility, a subsequent phase 3 trial evaluating ravulizumab abandoned concurrent placebo comparators as unethical, utilizing data from the earlier eculizumab trial as an external comparator instead—an approach successfully accepted by regulators.
China’s National Medical Products Administration, restructured in 2018 from the former China Food and Drug Administration into its current form under the State Administration for Market Regulation, has accelerated its review pathways in recent years.
Between 2001 and 2016 the agency approved only about 100 new drugs, roughly one-third of Western totals, but has since cut approval times from six or seven years to two or three while accepting overseas clinical-trial data, enabling the rapid clearances of satralizumab and inebilizumab that preceded the obinutuzumab beta study.
| Treatment Arm | Relapse Rate (%) | Hospitalization Required | Expanded Disability Status Scale Worsening (%) |
|---|---|---|---|
| Obinutuzumab β (MIL62) | 4.4% | Yes (for relapses) | 8.4% |
| Placebo Group | 45.7% | Yes (all relapses) | 22.9% |
Regulatory Precedents and Future Research Directions
The ongoing discourse surrounding the obinutuzumab beta trial highlights a critical friction point between rigorous clinical validation and patient protection in neuroimmunology. As Nature Medicine points out, the availability of multiple approved alternatives alters the ethical calculus of modern trial design. Regulatory bodies, investigators, and ethics committees face mounting pressure to prioritize external comparators and non-inferiority frameworks in rare autoimmune conditions where effective therapies are already established standard of care.
References
- Wu, L., Gu, L., Fan, W. et al. Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial. Nature Medicine (2026). https://doi.org/10.1038/s41591-026-04583-4
- World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects.
- National Medical Products Administration (NMPA). Regulatory approvals for neuromyelitis optica spectrum disorder therapeutics in China (2021–2025).